initial treatment, a blood sample will be obtained to derive 
lymphocytes which will be immortalized using the Epstein-Barr 
virus. An aliquot of these cells will be further infected with 
an amphotropic HLA-B7 retroviral vector, and expression will be 
confirmed on the cell surface. These cells will subsequently be 
used in the laboratory as target cells for the cytolytic T cell 
assay. At no time will these cells be brought into the same 
building where the patient is being treated. These cells and 
laboratory experiments will be performed in MSRB II, Room 3560, 
whereas the patient's clinical treatment will be taking place in 
the Clinical Research Center of The University of Michigan 
Medical Center Hospital. 
6.4 Repeated treatment. 
If no adverse side effects of the treatment are observed, 
repeated injections will be considered at two-week intervals. 
Doses identical to the initial treatment regimen will be repeated 
with similar protocols and observation as described in Section 
6 . 1 . 
6.5 Postmortem analysis. 
The life expectancy of patients who enter this protocol will 
be limited, in general, less than six months. Important 
information can be obtained by analysis of tissue postmortem, 
including presence of DNA in germ line tissue, distribution of 
DNA and immune function, and potential toxicity. To maximize the 
information derived from these studies, every effort will be made 
to perform postmortem analyses. Consent for an autopsy will not 
be required for entry, but patients and their families will be 
[412] 
Recombinant DNA Research, Volume 15 
